REFERENCES
1. Ojeda P, Sastre J, Olaguibel JM, Chivato T, investigators participating in the National Survey of the Spanish Society of A, Clinical Immunology A. Alergologica 2015: A National Survey on Allergic Diseases in the Adult Spanish Population. J Investig Allergol Clin Immunol. 2018;28(3):151-164.
2. Mayorga C, Fernandez TD, Montanez MI, Moreno E, Torres MJ. Recent developments and highlights in drug hypersensitivity. Allergy.2019;74(12):2368-2381.
3. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-437.
4. Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clinical and translational allergy.2017;7:7.
5. Tanno LK, Torres MJ, Castells M, Demoly P, Joint Allergy A. What can we learn in drug allergy management from World Health Organization’s international classifications? Allergy. 2018;73(5):987-992.
6. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy.2004;59(11):1153-1160.
7. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45-51.
8. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations.Allergy. 2003;58(9):854-863.
9. Pichler WJ. Delayed drug hypersensitivity reactions. Annals of internal medicine. 2003;139(8):683-693.
10. Fernandez TD, Mayorga C, Torres MJ, et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy. 2008;63(6):712-719.
11. Chaves P, Torres MJ, Aranda A, et al. Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams. Allergy. 2010;65(12):1600-1608.
12. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-1471.
13. Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71(8):1103-1134.
14. Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: In vitro testing. J Allergy Clin Immunol. 2019;143(1):56-65.
15. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy. 2008;63(2):181-188.
16. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy.2007;62(12):1439-1444.
17. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-820.
18. Luque I, Leyva L, Jose Torres M, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions.Allergy. 2001;56(7):611-618.
19. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol. 2006;118(4):949-956.
20. Rozieres A, Hennino A, Rodet K, et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy.2009;64(4):534-542.
21. Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. The British journal of dermatology.2013;168(3):539-549.
22. Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy. 2013;43(9):1027-1037.
23. Sachs B, Erdmann S, Malte Baron J, Neis M, al Masaoudi T, Merk HF. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy.2002;32(5):736-744.
24. Mayorga C, Dona I, Perez-Inestrosa E, Fernandez TD, Torres MJ. The Value of In Vitro Tests to DiminishDrug Challenges. International journal of molecular sciences. 2017;18(6).
25. Ebo DG, Leysen J, Mayorga C, Rozieres A, Knol EF, Terreehorst I. The in vitro diagnosis of drug allergy: status and perspectives.Allergy. 2011;66(10):1275-1286.
26. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol. 2010;125(2):411-418 e414.
27. Antunez C, Barbaud A, Gomez E, et al. Recognition of iodixanol by dendritic cells increases the cellular response in delayed allergic reactions to contrast media. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.2011;41(5):657-664.
28. Lopez S, Torres MJ, Rodriguez-Pena R, et al. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. The British journal of dermatology.2009;160(2):259-265.
29. Demoly P, Bousquet J. Drug allergy diagnosis work up.Allergy. 2002;57 Suppl 72:37-40.
30. Aguirre C, Garcia M. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].Med Clin (Barc). 2016;147(10):461-464.
31. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-712.
32. Barbaud A, Goncalo M, Bruynzeel D, Bircher A, European Society of Contact D. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact dermatitis. 2001;45(6):321-328.
33. Chiriac AM, Rerkpattanapipat T, Bousquet PJ, Molinari N, Demoly P. Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity. Allergy. 2017;72(4):552-561.
34. Gomez E, Diaz-Perales A, Tordesillas L, et al. Effect of Pru p 3 on dendritic cell maturation and T-lymphocyte proliferation in peach allergic patients. Ann Allergy Asthma Immunol. 2012;109(1):52-58.
35. Fernandez-Santamaria R, Palomares F, Salas M, et al. Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema. Allergy. 2019;74(9):1769-1779.
36. Torres MJ, Adkinson NF, Jr., Caubet JC, et al. Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing. The journal of allergy and clinical immunology In practice. 2019;7(1):40-45.
37. Martin M, Wurpts G, Ott H, et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry.Allergy. 2010;65(1):32-39.
38. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy. 1997;27(2):175-181.
39. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001;31(9):1398-1408.
40. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. Journal of immunology. 2011;187(1):200-211.
41. Zawodniak A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy. 2010;65(3):376-384.
42. Kuechler PC, Britschgi M, Schmid S, Hari Y, Grabscheid B, Pichler WJ. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy. 2004;59(6):613-622.
43. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature medicine. 2008;14(12):1343-1350.